Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
E. V. Borodavina,
P. A. Isaev,
A. Yu. Shurinov,
P. O. Rumyantsev,
V. V. Krylov,
K. M. Petrosyan,
A. D. Kaprin,
S. A. Ivanov,
S. O. Podvyaznikov,
I. S. Romanov,
A. M. Mudunov,
K. Yu. Slashchuk,
R. S. Zhikhorev,
M. V. Volkonsky,
R. M. Chagova,
I. R. Suslova,
A. I. Khryapa,
A. Kh. Lepshokova,
N. L. Fadeeva,
A. R. Safarova,
L. P. Kaleykina,
E. V. Lymar,
E. M. Chernyakova,
O. A. Snezhko,
A. E. Zinkovskaya,
F. F. Mufazalov,
E. S. Kuzmina,
Yu. V. Druzhinina,
Sh. I. Musin,
M. R. Mukhitova,
A. I. Khasanova,
S. Z. Safina,
S. L. Kirienko https://doi.org/10.17650/2222-1468-2020-10-1-65-72
Abstract
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients.
The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation.
Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study.
Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.
Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation.
About the Authors
E. V. Borodavina
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
P. A. Isaev
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
A. Yu. Shurinov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
P. O. Rumyantsev
National Medical Research Center for Endocrinology, Ministry of Health of Russia
Russian Federation
11 Dmitriya Ulyanova St., Moscow 117036
Russian Federation
11 Dmitriya Ulyanova St., Moscow 117036
V. V. Krylov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
K. M. Petrosyan
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
A. D. Kaprin
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
S. A. Ivanov
A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
4 Koroleva St., Obninsk 249036
Russian Federation
4 Koroleva St., Obninsk 249036
S. O. Podvyaznikov
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Bld. 1, 2 / 1 Barrikadnaya St., Moscow 125993
Russian Federation
Bld. 1, 2 / 1 Barrikadnaya St., Moscow 125993
I. S. Romanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. M. Mudunov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
K. Yu. Slashchuk
National Medical Research Center for Endocrinology, Ministry of Health of Russia
Russian Federation
11 Dmitriya Ulyanova St., Moscow 117036
Russian Federation
11 Dmitriya Ulyanova St., Moscow 117036
R. S. Zhikhorev
Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
Russian Federation
6 Staropetrovsky Dr., Moscow 125130
Russian Federation
6 Staropetrovsky Dr., Moscow 125130
M. V. Volkonsky
Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
Russian Federation
6 Staropetrovsky Dr., Moscow 125130
Russian Federation
6 Staropetrovsky Dr., Moscow 125130
R. M. Chagova
S.P. Botkin City Clinical Hospital, Moscow Healthcare Department
Russian Federation
5 2nd Botkinsky Dr., Moscow 125284
Russian Federation
5 2nd Botkinsky Dr., Moscow 125284
I. R. Suslova
Oncological Dispensary No. 4, Moscow Healthcare Department
Russian Federation
7 Medikov St., Moscow 115304
Russian Federation
7 Medikov St., Moscow 115304
A. I. Khryapa
Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)
Russian Federation
68a Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
Russian Federation
68a Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
A. Kh. Lepshokova
Oncological Dispensary of Rostov Region
Russian Federation
9 Sokolov Ave., Rostov-on-Don 344006
Russian Federation
9 Sokolov Ave., Rostov-on-Don 344006
N. L. Fadeeva
S.G. Primushko Republican Clinical Oncologic Dispensary, Ministry of Health of the Udmurt Republic
Russian Federation
102 Lenina St., Izhevsk 426009, Udmurt Republic
Russian Federation
102 Lenina St., Izhevsk 426009, Udmurt Republic
A. R. Safarova
Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan
Russian Federation
29 Sibirsky Trakt St., Kazan 420029, Republic of Tatarstan
Russian Federation
29 Sibirsky Trakt St., Kazan 420029, Republic of Tatarstan
L. P. Kaleykina
Republican Clinical Oncological Dispensary of the Republic of Mordovia
Russian Federation
30 Ulyanova St., Saransk 430032, Republic of Mordovia
Russian Federation
30 Ulyanova St., Saransk 430032, Republic of Mordovia
E. V. Lymar
Clinical Oncology Dispensary No. 1, Ministry of Health of Krasnodar Region
Russian Federation
146 Dimitrova St., Krasnodar 350040
Russian Federation
146 Dimitrova St., Krasnodar 350040
E. M. Chernyakova
Republican Oncological Dispensary of the Republic of Karelia
Russian Federation
5 Lososinskoe Hwy, Petrozavodsk 185002
Russian Federation
5 Lososinskoe Hwy, Petrozavodsk 185002
O. A. Snezhko
Oncological Dispensary of Rostov Region
Russian Federation
9 Sokolov Ave., Rostov-on-Don 344006
Russian Federation
9 Sokolov Ave., Rostov-on-Don 344006
A. E. Zinkovskaya
5City Clinical Oncology Dispensary
Russian Federation
56 Veteranov Ave., Saint Petersburg 198255
Russian Federation
56 Veteranov Ave., Saint Petersburg 198255
F. F. Mufazalov
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
Russian Federation
73 / 1 Oktyabrya Ave., Ufa 450054
Russian Federation
73 / 1 Oktyabrya Ave., Ufa 450054
E. S. Kuzmina
Regional Cancer Center, Salekhard District Clinical Hospital
Russian Federation
39 Mira St., Salekhard 629002
Russian Federation
39 Mira St., Salekhard 629002
Yu. V. Druzhinina
Multidisciplinary Clinical Medical Center “Medical City”
Russian Federation
32 Barnaulskaya St., Tyumen 625041
Russian Federation
32 Barnaulskaya St., Tyumen 625041
Sh. I. Musin
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
Russian Federation
73 / 1 Oktyabrya Ave., Ufa 450054
Russian Federation
73 / 1 Oktyabrya Ave., Ufa 450054
M. R. Mukhitova
Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
A. I. Khasanova
Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
S. Z. Safina
Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
Russian Federation
29 Sibirsky Trakt St., Kazan 420029
S. L. Kirienko
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Bld. 1, 2 / 1 Barrikadnaya St., Moscow 125993
Russian Federation
Bld. 1, 2 / 1 Barrikadnaya St., Moscow 125993
References
1. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. 236 c. [State of cancer care in Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2019. 236 р. (In Russ.)].
2. Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии радиойодрезистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;(3):4–9. [Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Сriteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;(3):4–9. (In Russ.)]. DOI: 10.17650/2222-1468-2014-0-3-4-9.
3. Нечаева О.А., Бавыкина Л.Г., Древаль А.В. Дифференцированный рак щитовидной железы: современные подходы к диагностике, терапии и динамическому наблюдению (обзор). Русский медицинский журнал 2016;(1):9–12. [Nechaeva O.A., Bavykina L.G., Dreval A.V. Differentiated thyroid cancer: modern approaches to diagnosis, therapy and dynamic monitoring (review). Russky meditsinky zhurnal = Russian Medical Journal 2016;(1):9–12. (In Russ.)].
4. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9.
5. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.
6. Thyroid carcinoma. NCCN guidelines. Available at: NCCN v1.2019https://www. nccn.org/professionals/physician_gls/pdf/ thyroid.pdf.
7. Исаев П.А., Семин Д.Ю., Румянцев П.О. и др. Клинический опыт применения препарата ленвантиниб у пациентов с прогрессирующим дифференцированным раком щитовидной желез, рефрактерным к терапии радиоактивным йодом. Опухоли головы и шеи 2016;6(2):65–9. [Isaev P.A., Semin D.Y., Rumyantsev P.O. et al. Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2016;6(2):65–9. (In Russ.)]. DOI: 10.17650/2222-1468-2016-6-2-65-69.
8. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI: 10.1016/j. ejca.2008.10.026.
9. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Available at: https://www.eortc.be/services/doc/ctc/ CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf.
10. IBM SPSS Statistics. Available at: http:// www.predictive.ru/software/statistics.htm.
11. StatSoft. Available at: http://statsoft.ru.
12. Инструкция по медицинскому применению препарата ленватиниб. Регистрационный номер ЛП-003398 (с изменениями от 26.02.2019). Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=114f1065-4daa-4dc49d0f-0ee1ee14377e&t= [Instruction on medical use of lenvatinib. Registration number ЛП-003398 (as amended on 26.02.2019). Available at: https://grls. rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=114f1065-4daa-4dc49d0f-0ee1ee14377e&t= (In Russ.)].
13. Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6): 699–704. DOI: 10.1530/ERC-18-0049.
Review
For citations:
Borodavina E.V., Isaev P.A., Shurinov A.Yu., Rumyantsev P.O., Krylov V.V., Petrosyan K.M., Kaprin A.D., Ivanov S.A., Podvyaznikov S.O., Romanov I.S., Mudunov A.M., Slashchuk K.Yu., Zhikhorev R.S., Volkonsky M.V., Chagova R.M., Suslova I.R., Khryapa A.I., Lepshokova A.Kh., Fadeeva N.L., Safarova A.R., Kaleykina L.P., Lymar E.V., Chernyakova E.M., Snezhko O.A., Zinkovskaya A.E., Mufazalov F.F., Kuzmina E.S., Druzhinina Yu.V., Musin Sh.I., Mukhitova M.R., Khasanova A.I., Safina S.Z., Kirienko S.L. Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation. Head and Neck Tumors (HNT). 2020;10(1):65-72. (In Russ.) https://doi.org/10.17650/2222-1468-2020-10-1-65-72
Views:
1639
Email this article 